Clinical trials: Indolent Non Hodgkin Lymphoma
Indolent B-cell NHL
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
- Trial name
- ROBIN (NCT01289223)
- Testing
- Bendamustine IV, Treatment of Physicians Choice
- Where
- 3 sites in Australia, Slovakia
- Volunteers
- 88 people
- Sponsor
- Mundipharma Research Limited
Non-Hodgkins Lymphoma
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an…
- Trial name
- NCT00179673
- Testing
- Lenalidomide
- Where
- 15 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Celgene
Non-Hodgkins Lymphoma
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
The primary objective of this Phase 3 study is to definitively confirm the safety and efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of…
- Trial name
- BiovaxID (NCT00091676)
- Testing
- FNHLId1, KLH + GM-CSF
- Volunteers
- 629 people
- Sponsor
- Biovest International
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01799889
- Testing
- Entospletinib MM, Entospletinib SDD
- Where
- 48 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- Gilead Sciences
Indolent B-Cell Non-Hodgkin's Lymphomas
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.
- Trial name
- NCT04569838
- Testing
- Bendamustine hydrochloride injection
- Where
- 11 sites in China
- Volunteers
- 91 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Hodgkin's Lymphoma
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued…
- Trial name
- NCT01059630
- Testing
- Obinutuzumab, Bendamustine
- Where
- 121 sites in United States, Austria and 12 more
- Volunteers
- 413 people
- Sponsor
- Genentech, Inc.
Indolent Non-Hodgkin Lymphoma
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
- Trial name
- TEMPO (NCT04038359)
- Testing
- Duvelisib
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 103 people
- Sponsor
- SecuraBio
Lymphoma, Non-Hodgkin
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
- Trial name
- TRANSCEND FL (NCT04245839)
- Testing
- Fludarabine, Cyclophosphamide, JCAR017
- Where
- 49 sites in United States, Austria and 8 more
- Volunteers
- 276 people
- Sponsor
- Celgene
Lymphoma
Fludara (Oral) Phase II Study for Indolent Lymphoma
To assess the antitumor effect and safety of Fludara in patients with indolent lymphoma.
- Trial name
- NCT00688883
- Testing
- Fludarabine Phosphate (Fludara)
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
CC-122-NHL-001 study is a multicenter, open-label, phase Ib study with dose escalation and expansion parts. It evaluates the safety, tolerability and clinical pharmacokinetics of CC-122 in combination with obinutuzumab (GA101).
- Trial name
- NCT02417285
- Testing
- Obinutuzumab, CC-122
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Indolent Non Hodgkin's Lymphoma (iNHL), Chronic Lymphocytic Leukaemia (CLL)
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region.
- Trial name
- NADIR (NCT02273856)
- Where
- 8 sites in Jordan, Kuwait and 5 more
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma International B.V.
Lymphoma Non-Hodgkin
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose…
- Trial name
- NCT02342665
- Testing
- Copanlisib (BAY80-6946)
- Where
- 13 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Bayer
Non-Hodgkin Lymphoma
A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
The primary objective of the study is to determine the overall response rate (ORR), which includes complete response (CR) and partial response (PR), to bendamustine treatment in participants with indolent non-Hodgkin lymphoma…
- Trial name
- NCT01596621
- Testing
- Bendamustine hydrochloride
- Where
- 27 sites in China
- Volunteers
- 102 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells.
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT05003141
- Testing
- PSB202
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 110 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Chronic Lymphoid Leukemia, Lymphoid Malignancies
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies.
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma
- Trial name
- NCT00406809
- Testing
- ABT-263
- Where
- 12 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
The purpose of the current study is to evaluate additional safety data of bendamustine in up to 100 patients with Indolent Non-Hodgkin's Lymphoma (iNHL) relapsing from a rituximab regimen or Chronic Lymphocytic Leukemia (CLL).
- Trial name
- BENDACT (NCT01500083)
- Testing
- Bendamustine at a dose of 100 mg/m2, Bendamustine at a dose of 120 mg/m2
- Where
- 16 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Lundbeck Canada Inc.
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Non-Hodgkin Lymphoma by Clinical Course
Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma
The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.
- Trial name
- NCT01570049
- Testing
- Bendamustine
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd